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Simple Summary: Carcinoma of the cortical region of the adrenal (ACC) is a rare and aggressive
cancer often with poor prognosis and limited therapies. For these reasons, tumor markers for early
diagnosis and monitoring the therapy and tumor evolution are required. This paper demonstrates in
a cohort of 19 patients affected by ACC, that in a simple blood draw (liquid biopsy), different cells
associated with the tumor can be found in samples taken before and after surgery. Among them,
the number of circulating tumor cells in blood samples taken before surgery can be predictive of
the patients’ survival and tumor recurrence, thus contributing valuable information on the tumor,
which may contribute to improve patient management and follow up. Further studies on larger
cohorts of ACC patients are required to validate this novel finding.
Abstract: Adrenocortical carcinoma (ACC), a rare and aggressive neoplasia, presents poor prognosis
when metastatic at diagnosis and limited therapies are available. Specific and sensitive markers
for early diagnosis and a monitoring system of therapy and tumor evolution are urgently needed.
The liquid biopsy represents a source of tumor material within a minimally invasive blood draw that
allows the recovery of circulating tumor cells (CTCs). CTCs have been recently shown to be detectable
in ACC. In the present paper, we evaluated the prognostic value of CTCs obtained by size-filtration
in a small pilot cohort of 19 ACC patients. We found CTCs in 68% of pre-surgery and in 38% of
post-surgery blood samples. In addition, CTC clusters (CTMs) and cancer associated macrophages
(CAMLs) were detectable in some ACC patients. The median number of CTCs significantly decreased
after the mass removal. Finally, stratifying patients in high and low pre-surgery CTC number
groups, assuming the 75th percentile CTC value as cut-off, CTCs significantly predicted patients’
overall survival (log rank = 0.005), also in a multivariate analysis adjusted for age and tumor stage.
In conclusion, though preliminary and performed in a small cohort of patients, our study suggests
that CTC number may represent a promising marker for prognosis and disease monitoring in ACC.
Keywords: CTCs; ACC; prognosis; adrenocortical cancer; liquid biopsy; cancer biomarker
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1. Introduction
Adrenocortical carcinoma (ACC) is a rare aggressive and heterogeneous neoplasia, with an
evolution strictly depending on early diagnosis, as the five-year survival in the metastatic forms
drops down to 0–28% according to the different series [1]. The challenge in the management of
advanced adrenocortical carcinoma depends on the paucity of the pharmacological approaches [1],
which are limited to mitotane (MTT) alone or combined with etoposide, doxorubicin and cisplatin
(EDP) treatment [2], with a variable range of efficacy. This still makes the radical resection of the
mass the best therapeutic option for early stage resectable ACC [3]. For these reasons, specific and
sensitive markers for early diagnosis and for monitoring the therapy and the tumor evolution are
urgently needed.
The blood liquid biopsy represents an incredible source of tumor material obtained by a simple
and minimally invasive procedure, such as a blood drawing [4,5]. Among the tumor material recovered,
circulating tumor cells (CTCs) have now gained importance in the oncology field as biomarkers of
the tumor development [6]. They are the most informative marker of the tumor status and of the
invasive/metastatic potential, as they might also contain cells able to trigger the metastatic process [7].
We have previously demonstrated the specific presence of CTCs in ACC, suggesting that they may
represent a good marker for this tumor [8]. CTC count has been so far recognized to have a significant
diagnostic and prognostic value as an independent factor in some solid tumors [9], particularly in breast
cancer [10–13], where its power as quantitative biomarker of the tumor response to chemotherapy has
been suggested [14].
Significant differences in the survival rate between metastatic patients affected by breast,
prostate and colon cancer with less than few CTCs in the blood sampling and those showing a
higher number of cells have been reported, with a cut-off depending on the tumor and the CTC
separation technique [11,15,16], determining an initial focus of the research on the CTC number.
The identification of CTCs into the bloodstream represents a technical challenge because of the limited
number of tumor cells with respect to blood cells. Among the available methods for CTC detection,
size-filtration techniques are relatively simple, providing the fractioning of the whole blood in a single
step and preserving the cell integrity for CTC detection and further characterization [17]. In the present
paper, in a monocentric preliminary study conducted on 19 ACC patients, we assessed the validity of
CTC number obtained by blood filtration as an independent prognostic marker, as well as the potential
use of CTCs to monitor the disease evolution and response to therapy during the patients’ follow-up.
2. Results
We analyzed a cohort of n = 19 patients with ACC diagnosis, where at least four ScreenCellTM
cytologic filters had been obtained from independent pre-surgery (PreS) and post-surgery (PostS)
blood samples. The patients’ characteristics and clinical data are reported in Table 1.
The filters were stained with May–Grünwald–Giemsa or with hematoxylin and eosin for CTC
morphometric analysis, cell identification and count [8], as shown in Figure 1. CTC positivity for
steroidogenic factor-1 (SF-1) was detected by immunocytochemistry performed in parallel filters
obtained from the same blood sample used to confirm CTC adrenocortical origin (inset in panel D,
Figure 1). The stained filters obtained in duplicate from blood samples taken before (time interval:
−3/+2 months) and after surgical removal of the ACC mass (time interval: +3–80 months) were analyzed
by the referent pathologist. We found detectable CTCs in 15/19 patients (79%) in PreS filters and in
13/19 patients (68%) in at least one PostS filters; moreover, considering the filter analysis—45/66 (68%)
of PreS filters and 80/209 (38%) of PostS filters had positive readings.
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Table 1. Characteristics of the adrenocortical carcinoma (ACC) patients and of the tumors along with
circulating tumor cell (CTC) number in pre-surgery (PreS) and post-surgery (PostS) blood samples.
Data from the whole cohort of patients or when patients were stratified in low and high number of
















11.0 ± 4.5 21.4 ± 11.0 6.8 ± 1.2
I: 2 (10%) NO: 4 (21%)
1.7 [1–9] 0.6 [0.1–1.2]II: 6 (32%) G: 10 (53%)
M:10 (53%) III: 7 (37%) A: 4 (21%) (0–30) (0–5.2)








11.2 ± 4.6 20.4 ± 11.6 6.7 ± 1.2
I: 1 (8%) NO: 2 (17%)
1.1 [1–2.0] 0.6 [0–0.9]II: 4 (33%) G: 6 (50%)
M: 5 (42%) III: 7 (59%) A: 3 (25%) (0–6.6) (0.1–1.1)








9.6 ± 5.4 27.5 ± 9.6 7.8 ± 1.0
I: 1 (14%) NO: 2 (29%)
17 [9–24] 0.3 [0–0.3]II: 2 (29%) G: 4 (57%)
M: 3 (43%) III: 0 (0%) A: 1 (14%) (9–30) (0–1)
IV: 4 (57%) M: 0 (0%)
Data are expressed as mean ± SD for parametric (age, tumor diameter, Weiss, Ki67%), or median [25–75 percentiles]
for non-parametric continuous variables, and as absolute number and percentage of patients for non-continuous
variables (sex, stages, secretion type—G: glucocorticoids, A: androgens, M: mineralocorticoids). Data intervals







































































morphometric analysis, cell  identification and count  [8], as shown  in Figure 1. CTC positivity  for 
steroidogenic  factor‐1  (SF‐1) was detected by  immunocytochemistry performed  in parallel  filters 
obtained from the same blood sample used to confirm CTC adrenocortical origin (inset in panel D, 
Figure 1). The stained filters obtained in duplicate from blood samples taken before (time interval: 





Figure 1. Representative staining with hematoxylin and eosin (H&E) and May–Grünwald–Giemsa
(MGG) of circulating cells enriched by ScreenCell filters from blood samples of ACC patients.
Circulating tumor cells (CTCs, A,D), circulating tumor microemboli (CTMs, B,E), and cancer associated
macrophages (CAMLs, C,F) were separated by ScreenCell devices from blood samples of ACC patients
(magnification: 40×) and stained with hematoxylin and eosin (H&E) or May-Grünwald Giemsa
(MGG). A polymorphonuclear leukocyte with the typical multilobated nuclei is indicated by the arrow
(D) for comparison with a CTC. The small pores of 6 µm are visible as small dots non homogenously
distributed on the filter membrane. Inset in panel (D) shows the nuclear positivity to steroidogenic
factor-1 (SF-1) antibody in a representative CTC obtained in a parallel filter from the same blood sample.
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In addition to single CTC, CTC clusters (named circulating tumor microemboli, CTMs,
n = 4 patients) and cancer associated macrophages (CAMLs, n = 7 patients) were also found in
some ACC patients (Figure 1). In 50% of cases, CAML were associated with CTMs (χ2 = 5.7, p = 0.017).
The median CTC number and interval of PreS- and PostS-CTCs are reported in Table 1 for the
whole cohort of ACC patients. The analysis demonstrated a statistically significant decrease in the
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were available, the median number of CTC was used for the analysis; * the lowest and the highest 









Figure 2. CTC distribution in pre-surgery and post-surgery blood sa ples in ACC patients. Box charts
indicate CTC number distribution betw en pre-surgery (PreS-CTCs) and post-surgery (PostS-CTCs)
blood sa l s i t ti cohort of ACC patients (TOT AC ), and when the coh rt was stratified in low
and high CTC number in P eS blood samples classes according to the cut off of 9 CTCs (75th percentile
of the non-parametric distributions of PreS CTCs). For each patient, when multiple samples w re
avail ble, the median number of CTC was used for the analysis; * the lowest and the hig st values
for ach group a e indicated. As paired PreS and PostS samples were not available for l patients,
diff rences b tween the two groups of data were analyzed by the Mann–Whitney U test for indep ndent
on-parametric data, th resulting p values are indicat d.
Table 1 also re orts t e atients’ clinical data and TC nu bers in PreS and PostS sa ples of
patients stratifie i lo and high PreS CTC count. The cut off value for this stratification was 9.0 and
1.2 CTCs isolated from 3 mL of blood, corresponding to the values of the 75th percentile non-parametric
distributions of the CTC number, respectively, in PreS and PostS samples. The decrease in CTC median
after surgery was statisticall significant for both low and high PreS CTC groups (Figure 2).
CTC count differed among patients and at the follow-up. In some patients receiving only MTT
therapy—chosen for the multiple blood sampling and filters obtained (≥5)—the behavior of CTC count
during the follow-up was associated with MTT response and tumor recurrence (Figure 3A–C).














patients considered, where MTT  levels and CTCs were evaluated  in blood samples drawn on  the 
same day (Figure 4). 
Figure 3. Distribution of CTCs in blood samples during the follow-up of three representative ACC
patients. The numbers of CTCs separated and counted on nCell filters in each blood sample at the
indicated time of follow-up are represented. Arrows indicate T = 0 corresponding to tumor removal
(surgery), the initiation of mitotane (MTT) therapy and the stop of therapy at five years from surgery
(60 months). (A) patient, stage II, R0; (B) patient, stage III, R0, the additional arrow indicates surgery
for a retroperitoneal lymph node diagnosed at month 6; (C) patient stage III, R0.
A statistically significant negative association as found between MTT and CTCs in the three

























PreS was able  to significantly predict OS  (log  rank = 0.005, Figure 5A) but not DFS  (not  shown), 
confirming  the  absence  of  a  significant  correlation  between  PreS  low/high  CTC  number  and 
recurrence. 
Figure 4. Association between mitotane (MTT) levels and TC numbers evaluated in the same blood
sample in three ACC patients receiving MTT only as post-surgery chemotherapy. A statistically
significant negative linear correlation was found between CTC number counted on ScreenCell device
(ordinate) and MTT levels (abscissa); R = −0.661, R2 = 0.437, p = 0.007, n = 15.
Cancers 2020, 12, 3176 6 of 13
We then assessed the predictive power of the CTC number obtained in blood samples drawn
before the tumor mass removal. Statistical analysis between CTC number in PreS samples and all
ACC clinical parameters of ACC (stage, tumor diameter, secretion, Weiss score, stage, number of
mitosis, Ki67%) showed a significant positive correlation only with the Weiss score (R = 0.537, p = 0.032)
and with the metastatic stage IV (R = 0.517, p = 0.028).
In order to identify factors that were the best candidate to influence the patients’ follow up,
we performed a correlation analysis that identified stage and PreS low/high CTC number to positively
and significantly associate with death (R = 0.479, p = 0.038 and R = 0.717, p = 0.001, respectively),
as well as stage and tumor treatment (mitotane only or plus other chemotherapies) with recurrence
(R = 0.554, p = 0.014 and R = 0.478, p = 0.039, respectively). Conversely, no significant correlation
was found between the tumor treatment with death, and PreS low/high CTC number with recurrence
(not shown).
We analyzed the prognostic power of the CTC number before and after surgery for disease-free
survival (DFS) and overall survival (OS) by applying Kaplan–Meier analysis to patients stratified in
high and low numbers of CTCs in PreS and PostS blood samples. No significant predictive power
for PostS CTC number was found (not shown). Conversely, the 75th percentile cut off value obtained
in PreS was able to significantly predict OS (log rank = 0.005, Figure 5A) but not DFS (not shown),




patients.  Overall  survival  (OS)  Kaplan–Meier  curves  evaluated  in  the whole  cohort  of  patients 
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hazard ratio (HR) (95%confidence interval, CI) in univariate and multivariate model for the indicated 
parameters. Significant p values are indicated in italics. 
  HR (95%CI) Unadjusted  p  HR (95%CI) Adjusted  p 
Pre‐S CTCs  12.0 (1.3–110.0)  0.026  22.0 (0.9–540.0)  0.05 
Age  1.05 (0.99–1.11)  0.120  0.98 (0.86–1.10)  0.675 









Figure 5. Comparison between the overall survival predictive value of CTC count and stage in ACC
patients. Overall survival (OS) Kaplan–Meier curves evaluated in the whole cohort of patients according
to stratification in low/high classes of CTC count in PreS samples (cut off value: 9 cells/3 mL) (A),
in metastatic vs. non-metastatic classes (stage IV vs. I–III) (B), and in aggressive vs. non-aggressive
classes (stage III–IV vs. I–II) (C). Stratification of aggressive stage III–IV patients according to low/high
classes of CTC count in PreS samples (D). Log rank and χ2 values are indicated as well as the number
of patients in each class.
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The risk of death (hazard ratio, HR) associated with PreS CTC number was still statistically
significant in a multivariate Cox regression analysis after adjusting for age and stage, as shown in
Table 2.
Table 2. CTC number in pre-surgery blood samples is the best predictor of death risk in ACC patients.
Univariate (unadjusted) and multivariate (adjusted) Cox regression analysis of the risk of death
hazard ratio (HR) (95%confidence interval, CI) in univariate and multivariate model for the indicated
parameters. Significant p values are indicated in italics.
HR (95%CI) Unadjusted p HR (95%CI) Adjusted p
Pre-S CTCs 12.0 (1.3–110.0) 0.026 22.0 (0.9–540.0) 0.05
Age 1.05 (0.99–1.11) 0.120 0.98 (0.86–1.10) 0.675
Stage 4.37 (1.2–15.75) 0.024 3.78 (0.7–19.7) 0.114
Italics indicates a statistically significant p value compared to non-significant.
Interestingly, according to the Kaplan–Meier analysis, the ability of PreS CTC number to predict the
patient survival (log rank = 0.005, χ2 = 7.9) was comparable to the metastatic stage IV (log rank = 0.000,
χ2 = 11.3, Figure 5B), while tumor aggressiveness (dichotomized in two classes of low and high
aggressiveness according to stage I–II vs. stage III–IV, respectively) was not a statistically significant
parameter (Figure 5C). Finally, in the aggressive stage (stage III–IV), PreS CTC number significantly
predicted OS, further refining patients’ stratification (log rank = 0.000, χ2 = 12.0, Figure 5D).
3. Discussion
Moving further from our previous publication where we showed the presence of CTCs in blood
samples from patients with ACC [8] and suggested a diagnostic value for CTCs, in the present paper,
we demonstrate the prognostic value of CTC count in the preoperative blood samples of ACC patients.
Moreover, our findings indicate that CTCs represent a novel marker obtained through minimally
invasive blood sampling to monitor ACC status and evolution before and after surgery, as well as in
response to MTT therapy during the patient’s follow-up.
Interestingly, we found CTCs in nearly 68% of PreS blood samples independently from the patients’
stage. The percentage of CTC-positive samples as well as the median number of CTCs decreased
significantly within months after surgical removal of the mass. In particular, when patients were
stratified on the basis of high and low numbers of CTCs in PreS samples, the PostS CTC number
significantly decreased compared to PreS samples. Notably, the number of CTCs in PostS blood
samples seemed to reflect the removal of the tumor mass as well as the start of the MTT treatment
(two months from surgery). Accordingly, in patients treated post-surgery with MTT only, with no
combination with other chemotherapies, a negative correlation between circulating levels of MTT and
CTCs was found. Despite the strength of this association, the patients were very few, thus this result
needs to be further validated in a larger ACC cohort.
In the present paper, we showed that the tumor recurrence in some representative patients was
associated with a rapid increase in CTC number. These findings strongly suggest that CTC count may
represent a valid tool for the monitoring of patients during the follow-up. If this result was validated
in larger cohort of ACC patients, this might revolutionize the monitoring of patients as well as their
quality of life, allowing a strict and sensitive follow-up based only on a simple blood drawing.
The number of cells is so far the only CTC parameter with a recognized validity for both
tumor diagnosis and prognosis as well as for tumor monitoring [9,18]. The majority of these studies
have been performed in colorectal, breast, lung and prostate cancer, where CTC capture from the
blood has been performed by the CellSearch method [19], mainly based on capture by antibodies
against cytokeratins—a marker of the epithelial to mesenchymal transition (EMT). However, the EMT
phenomenon interests tumors developed in organs of epithelial origin, which is not the case in
ACC [7]. In this tumor, the CellSearch method is likely to underestimate the number of CTCs present
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in the bloodstream [7]. Conversely, in ACC, CTC recovery by size with ScreenCell filters has been
demonstrated to work efficiently [8]. The use of ScreenCell filters allows not only the detection of CTCs
but also of CTMs and in particular of CAMLs, which is not possible with the use of CellSearch. In fact,
in a small number of patients, in addition to CTCs, small clusters of CTCs, named CTMs, were also
found entrapped in the filters, along with CAMLs. A statistically significant positive correlation was
also found between blood samples with CTMs and circulating CAMLs. Interestingly, CAML presence
has also been described in some CTMs with other tumor associated stromal cells [20], although in blood
samples from ACC patients we only found CAMLs as single cells. CTMs have been described to detach
from the tumor mass as small aggregates of cells, suggesting that they actively migrate from the tumor
by a collective migration process and do not associate secondarily in the bloodstream [21]. In these
multicellular aggregates, CTCs have been hypothesized to be more resistant to apoptosis and be able
to survive also in the blood stream [21,22]. CAMLs are disseminated tumor-associated macrophages
(TAMs) with expressing engulfed organ-specific markers. TAMs’ role in cancer progression has
been described for the very first time in breast cancer, where they promote angiogenesis, tumor cell
migration, metastasis, and immune evasion [23]. CAMLs are highly differentiated giant phagocytic cells
of myeloid origin (CD14/CD11c) with large atypical nuclei or multiple individual nuclei, and epithelial
cell characteristics, often positive for CD45. The presence of CTMs and CAMLs has been described
to be associated with malignancy and poor prognosis in breast cancer [20,24–27] and other solid
tumors [28]. Although found in 36% of our patients and with a significant correlation with CTMs,
the small dimension of our cohort, due to the rarity of ACC compared to breast cancer, did not permit
the analysis of the prognostic value of either CAMLs or CTMs.
Conversely, we were able to assess the predictive role of single CTC number in both pre-and
post-surgery blood samples. In fact, Kaplan–Meier analysis of ACC patients stratified in low and high
subgroups based on PreS CTC number demonstrated the ability to significantly predict the overall
survival. This relevant finding was obtained by a minimally invasive procedure that does not need
tumor removal, which is necessary to obtain the classical tumor pathological parameters. The cut-off
value proposed for CTCs in ACC is in line with the one established by the very first paper on breast
cancer [11] and with that currently adopted for other solid tumors [29]. Interestingly, although less
indicative than the metastatic stage, PreS CTC count was more efficacious in predicting OS than
aggressiveness, which became significant only when combined with CTC number. Notably, in our
cohort, only one patient (stage IV) did not undergo surgical removal of the ACC mass. This patient
was classified in the high CTC number PreS group with a poor prognosis, the filter also showed the
presence of two CAMLs. Indeed, the patient died within six months from ACC diagnosis. This patient,
who showed bone metastases at (18F)-Fluorodeoxyglucose positron emission tomography (18FDG-PET)
but could not be operated on and classified by classical tumor pathological parameters, is an example
of how a simple non-invasive blood drawing aimed at detecting CTC number may assume a valid
prognostic value. This type of patient, where staging is difficult as the tumor is not available and classical
tumor markers cannot be evaluated, although rare, would greatly benefit from the prognostic power
of CTC number, as detected by a simple minimally invasive blood drawing. However, CTC number
would also represent a powerful marker for tumor monitoring and its contribution to prognosis in all
ACC patients, independently from stage.
We recognize our study presents some limitations: i. the low number of patients analysed,
which is due to the rarity of the tumour; ii. the lack of preS and postS paired samples in some patients,
that determined the impossibility to perform a paired analysis; iii. the possible intra-patient variability
in the number of CTC found by a single blood sampling; iv. the hetherogeneity of chemotherapy
treatment, since some patients received mitotane and others received mitotane plus chemotherapy.
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4. Materials and Methods
4.1. Patients and Ethical Approval
All patients have been monitored for adrenocortical cancer pathology at the University Hospital
Azienda Ospedaliera Universitaria (AOU) Careggi. They have been enrolled in the study after
giving their written informed consent according to the approval by the local ethical committee
(prot. 2011/0020149, Rif CEAVC Em. 2019-201 26/11/2019).
All patients underwent surgical removal of the tumor except one, where ACC diagnosis was made
instrumentally by computed tomography (CT)/magnetic resonance imaging (MRI) tumor characteristics.
Among operated patients, n = 14 presented negative margins (R0) after surgery, while n = 4
had positive margins. Tumor samples were formalin-fixed, and paraffin embedded for histologic
and immunohistochemical analysis. All patients received MTT therapy (either before or after
surgery), of whom, n = 9 received MTT only and n = 10 MTT plus other chemotherapies (etoposide,
doxorubicin and cisplatin (EDP)).
4.2. Histologic Analysis and Immunohistochemistry of the Primary Tumour
Histologic diagnosis was performed by the reference pathologist on tumor tissue removed at
surgery (n = 18). Tumor specimens were evaluated according to the Weiss score system in which the
presence of three or more criteria highly correlates with malignant behavior [30,31]. The Ki67 labelling
index (Ki67) was evaluated as a proliferation marker to assess ACC prognosis using the anti-human
Ki67 antibody (1:40 dilution, clone name MIB-1, Dako, Carpenteria, CA, USA). Ki67 positive nuclei
were counted in 1000 tumor cells and Ki67 was expressed as the percentage of labelled cells.
Tumor stage was evaluated according to the revised TMN classification of ACC proposed by the
European Network for the Study of Adrenal Tumours (ENS@T) [32].
4.3. Blood Sample Collection
For each patient, 6 mL of blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes.
Sampling was performed before surgery or at different time points during post-surgical follow-up,
with a median (min-max) value of 16 (3–81) months. All blood samples were processed within 3 h after
collection [33], generating two filters, and then evaluated for CTC presence.
4.4. Mitotane Measurement
Mitotane was measured through the Lysosafe service (HRA Pharma, Châtillon, France) in serum
blood samples taken from ACC patients.
4.5. CTC Analysis
CTC analysis was performed through three sequential steps consisting of isolation from blood
by filtration on ScreenCell® Cyto filtration devices (ScreenCell, Paris, France), followed by CTC
identification through validated morphometric criteria [8,10].
4.5.1. CTC Isolation
Blood was filtered by the ScreenCell® Cyto filtration devices (ScreenCell), according to the
procedure previously described [8]. Briefly, before filtration, 3 mL blood samples were diluted in a
final volume of 7 mL with a specific dilution buffer for fixed cells (ScreenCell® FC dilution buffer,
ScreenCell). After filtration, an additional 1 mL of phosphate buffered saline (PBS) was filtered to
remove red blood cell (RBC) debris. Filtration was usually completed within approximately 50 s.
The filter was then disassembled from the filtration module and allowed to air dry. For each patient’s
blood sample, filtration was performed in duplicate.
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4.5.2. CTC Staining and Identification
Cytologic study was conducted directly on the filter. The track-etched filters were stained with
hematoxylin solution S (Merck KGaA, 64,271 Darmstadt, Germany), applied to the membrane for 1 min,
and Shandon eosin Y aqueous (Thermo Electron Corporation, Thermo Fisher Scientific Inc., Waltham,
MA, USA) for 45 s. Alternatively, on the second filter obtained from the same 6 mL blood sample,
May–Grünwald–Giemsa staining was performed. For microscopic observation, the ScreenCell®Cyto
filter was placed on a standard microscopy glass slide and a 7 mm circular cover slip (Menzel-Glaser,
Braunschweig, Germany) was laid on the filter with the appropriate mounting medium. CTCs were
identified according to the following morphologic criteria: cell size ≥16 µm, nucleocytoplasmic ratio
≥50%, irregular nuclear shape, hyperchromatic nucleus, and basophilic cytoplasm. Under these
criteria, red cells and platelets were not entrapped in the filters and leukocytes could be excluded [8].
Blinded cytological analysis was performed under optical microscopy by 2 independent observers
(GC and GN) on the 2 differently stained couple of filters (MGG and H&E).
4.5.3. Cytologic Characterization by Immunocytochemistry
To confirm the adrenocortical origin of isolated CTCs, we performed immunostaining for
steroidogenic factor-1 (SF-1) of a second filter obtained by the same blood sample, as previously
described [8]. Briefly, the filter was incubated for 5 min at room temperature with 70µL of permeabilizing
buffer and subjected to heat-induced epitope retrieval in a bath containing target retrieval solution
(S2367, Dako, Glostrup, Denmark) pH 9.0, at 99 ◦C for 20 min. After washing, the filter was stained
with the polyclonal antibody anti-steroidogenic factor 1 (cat #07-618 Upstate, Millipore, Billerica,
MA, USA). Staining was achieved by treating the filter with 70µL EnVision Detection System Peroxidase/
3.3′-Diaminobenzidine DAB, Rabbit/Mouse (K5007, Dako) for 40 min at room temperature followed by
the chromogen 3.3′ diaminobenzidine (Dako) for 10 min at room temperature. Each filter was then
placed on paraffin film and the nuclei were slightly counterstained with H&E for 6 min.
4.6. Statistical Analysis
Data were expressed as mean ± SD except for CTC number, which was non-normally
distributed (as assessed by Kolmogorov–Smirnov’s test) and expressed as median (25–75 percentile).
Statistical analysis was performed by SPSS 24.0 (Statistical Package for the Social Sciences,
Chicago, IL, USA) for Windows. p values of less than 0.05 were considered statistically significant.
Correlation analyses were carried out using a χ2 test for categorical and Pearson/Spearman test for
continuous variables, respectively. For each patient, when multiple samples were available, the median
number of CTCs was used for the analysis in both PreS and PostS samples. Comparison between two
groups of data was performed using the non-parametric Mann–Whitney U test and Student’s t test
for normally distributed variables. Overall survival (OS) and disease-free Survival (DFS) (defined as
the probability (ranging from zero to one) that a patient diagnosed with the disease is still alive (OS)
or is free from the disease (DFS) at a time point from surgery, for operated patients, or from diagnosis,
for not operated patients) and the relative curves were calculated using the Kaplan–Meier method.
Differences in OS and DFS between groups of stratification were assessed with log rank and Cox
proportional hazards after adjustment for age and stage.
5. Conclusions
Though preliminary, this is the first study that demonstrates the predictive power of CTC count
in blood liquid biopsy before having access to the tumor analysis through surgery. Our findings need
to be further validated in larger cohorts of patients by multicenter studies.
Standardization of studies on CTC evaluation and validation in larger prospective cohorts of ACC
patients is mandatory before we can definitely establish the clinical utility of this promising marker in
assessing the prognosis, monitoring the disease and guiding the treatment of ACC patients.
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